NOTE

Treatment of chytridiomycosis with reduced-dose itraconazole

Megan E. B. Jones1,4, David Paddock2, Lee Bender2, Jack L. Allen3, Mark D. Schrenzel1, Allan P. Pessier1,*

1Amphibian Disease Laboratory, Wildlife Disease Laboratories, Institute for Conservation Research, San Diego Zoo Global, San Diego, California 92112, USA
2Saratoga National Fish Hatchery, United States Fish and Wildlife Service, Saratoga, Wyoming 82331, USA
3Paul Harter Veterinary Medical Center, San Diego Zoo Safari Park, Escondido, California 92027, USA
4Present address: Department of Pathology, College of Veterinary Medicine, University of Georgia, 501 D. W. Brooks Drive, Athens, Georgia 30602, USA

ABSTRACT: Effective treatment methods to eliminate infection with Batrachochytrium dendrobatidis (Bd) are required for development of sustainable captive survival assurance populations of amphibians and to reduce the risk of introducing Bd to new locations as part of amphibian trade or reintroduction programs. Treatment with itraconazole baths at 100 mg l−1 is commonly used in captive amphibians, but side effects are observed in some amphibian species and life stages. Naturally occurring outbreaks of chytridiomycosis in Wyoming toads Anaxyrus baxteri and White’s tree frogs Litoria caerulea were treated with lower-dose itraconazole baths (e.g. 50 mg l−1 for White’s tree frogs) and followed post-treatment with serial Taqman PCR testing to confirm elimination of Bd infection. Post-treatment PCR tests were consistently negative for the presence of Bd and treatment was deemed successful. Although this was not a controlled clinical trial, results suggest that lower doses of itraconazole may be effective for treatment of chytridiomycosis with resulting cost savings to amphibian conservation programs and a potential for a reduction in dose-related side effects from itraconazole treatment. Prospective clinical trials of alternative itraconazole treatment protocols are encouraged.

KEY WORDS: Batrachochytrium dendrobatidis · Wyoming toad · Anaxyrus baxteri · White’s tree frog · Litoria caerulea

INTRODUCTION

The fungus Batrachochytrium dendrobatidis (Bd) causes the disease chytridiomycosis, implicated as a contributor to global amphibian population declines (Skerratt et al. 2007). Population declines due to chytridiomycosis occur rapidly, and measures to mitigate these effects in wild populations have not been introduced (Lips et al. 2006). As a result, there are efforts to develop rescue programs at sites of Bd-associated mortality events and to establish captive survival assurance populations of amphibians with the hope of later reintroducing species to the wild (Mendelson et al. 2006, Gagliardo et al. 2008). Success of survival assurance populations requires safe, effective and practical treatments to eliminate Bd infection, reduce the impact of chytridiomycosis on captive amphibians and pre-
vent movement of Bd to new locations as the result of translocation and reintroduction programs. The recent listing of Bd as a pathogen notifiable to the World Organization for Animal Health (OIE) will increase the need for reliable treatments to clear amphibians of infection for purposes of international shipment (Schloegel et al. 2010).

Treatment methods for Bd infection have recently been reviewed (Berger et al. 2010, Pessier & Mendelson 2010) and include elevated temperature (Woodhams et al. 2003, Chatfield & Richards-Zawacki 2011), formalin-malachite green (Parker et al. 2002), chloramphenicol (Bishop et al. 2009) and theazole-type antifungal drugs itraconazole, fluconazole and voriconazole (Martel et al. 2011). An empirically derived treatment protocol using itraconazole applied daily as a 100 mg l\(^{-1}\) bath (Nichols et al. 2000) has been widely adapted for treatment of chytridiomycosis in captive amphibians (Forzán et al. 2008, Gagliardo et al. 2008, Pessier 2008, Tammukai et al. 2011). Advantages of this protocol are that it is well tolerated by many amphibian species and only a short daily treatment period of 5 to 10 min is needed. Disadvantages include the high cost of treatment and reports of treatment-associated deaths in some species or life stages (Pessier & Mendelson 2010). There are no controlled clinical trials of itraconazole treatment in post-metamorphic amphibians and evaluations of treatment efficacy have mostly been limited to observation of clinical improvement or rely on insensitive methods to detect Bd infection (e.g. histology). A single report using the more sensitive PCR test to detect evidence of residual Bd infection after treatment examined only a small number of animals (Tammukai et al. 2011).

Many treatment methods for chytridiomycosis have disadvantages such as the inability of some species to tolerate elevated temperatures or toxicity concerns; therefore, further investigation on the use of drugs such as itraconazole is warranted. Reasoning that reducing the itraconazole dose could lower the risk for treatment side-effects while also reducing the cost of treatment, and encouraged by successful elimination of experimental Bd infection in tadpoles with minute doses of itraconazole (Garner et al. 2009), we used alternative dosing protocols of itraconazole to treat outbreaks of chytridiomycosis in 2 groups of captive anurans. Treated animals were followed after treatment by serial PCR testing to confirm elimination of Bd infection.

**MATERIALS AND METHODS**

**Case history: Wyoming toads**

The first outbreak occurred in a survival assurance population of 90 Wyoming toads Anaxyrus baxteri. In November 2009, there was an increase in toad deaths (10 animals over a 3-wk period) and formalin-fixed carcasses were submitted for histopathology. Histologic examination demonstrated severe epidermal hyperplasia and hyperkeratosis with myriad fungal thalli typical of Bd in 9 out of 10 toads (Fig. 1); a diagnosis of chytridiomycosis was made. The tenth animal had no histologic evidence of Bd infection and died of chronic kidney disease.

After diagnosis, treatment with itraconazole was initiated in the remaining 80 toads on 15 December 2009. Prior to treatment, samples for TaqMan PCR (see methods below) were collected from 46 of 80 animals, including at least 1 animal from each tank in the facility. Beginning 2 wk after cessation of treatment, all surviving animals were tested at 1-mo intervals for 5 mo. Each individual animal was tested on a single swab for the first 2 post-treatment tests whereas the later 3 tests consisted of pooled samples.

The treatment protocol used a commercial oral itraconazole solution (Sporanox Oral Solution, Janssen Pharmaceutica; 10 mg ml\(^{-1}\)) diluted in distilled water and administered via a shallow bath for 5 min daily for 10 d. The treatment solution was diluted to 100 mg l\(^{-1}\) for the first 3 d, followed by 5 mg l\(^{-1}\) for 6 d
and 50 mg l\(^{-1}\) for the last day. The inconsistent dosing schedule was the result of a communication error. After each treatment, animals were not rinsed and were placed into a freshly disinfected enclosure. Enclosures used during the treatment period were plastic tubs cleaned to remove organic waste, disinfected with diluted household bleach (0.018% sodium hypochlorite) for a minimum of 60 min, rinsed thoroughly with water and then allowed to dry completely for 24 h. Animals that died during treatment were preserved in 10% neutral buffered formalin and submitted for histopathology.

**Case history: White’s tree frogs and African bullfrogs**

The second outbreak occurred in a group of 17 White’s tree frogs *Litoria caerulea* housed in a room with 2 African bullfrogs *Pyxicephalus adspersus*. In January 2010, 6 White’s tree frogs died unexpectedly. Histologic examination of dead animals revealed severe epidermal hyperplasia and hyperkeratosis with myriad fungal thalli typical of *Bd*; a diagnosis of chytridiomycosis was made. Other necropsy findings included pneumonia and coelomitis associated with pigmented fungi (phaeohyphomycosis) in 1 of 6 frogs, acute renal tubular degeneration (2/6) and tissue migration of larval nematodes (1/6).

After diagnosis, treatment was initiated with itraconazole in the remaining 11 White’s tree frogs and 2 African bullfrogs. Prior to treatment, samples for TaqMan PCR (see methods below) were collected from all animals. Subsequently, beginning 2 wk after cessation of treatment, surviving animals were tested at 2-wk intervals for a total of 4 times over 8 wk. Testing was repeated in February 2011, 13 mo after cessation of treatment.

The treatment protocol used a commercial oral itraconazole solution (Sporanox Oral Solution, Janssen Pharmaceutica; 10 mg ml\(^{-1}\)) diluted in amphibian Ringer’s solution and administered via a shallow bath for 5 min daily for 10 d. The treatment solution was prepared daily and diluted to 50 mg l\(^{-1}\) for the entirety of the treatment course. After each treatment, animals were not rinsed and were placed into a new enclosure previously disinfected with 0.4% sodium hypochlorite (a 1:10 dilution of household bleach) for a minimum of 60 min contact time, thoroughly rinsed with water, and allowed to dry completely for 24 h. Animals that died during treatment were preserved in 10% neutral buffered formalin and submitted for necropsy and histopathology.

**Taqman PCR for Bd**

Samples for Taqman PCR were collected using a swabbing protocol that includes the ventral skin surfaces of the abdomen, legs and feet (Pessier & Mendelson 2010). Pooled samples in Wyoming toads used the same swab to sample 3 to 4 different toads from the same enclosure. Samples were collected on rayon-tipped, plastic-handled swabs (Dryswab™ Fine Tip MW113, Advantage Bundling SP/Medical Wire and Equipment). Briefly, Taqman PCR generally followed the method, primers and probe of Boyle et al. (2004) and Hyatt et al. (2007), including preparation of DNA template with Prepman Ultra® (Applied Biosystems) and the use of an exogenous internal positive control labeled with VIC™ (Applied Biosystems) for each sample to detect PCR inhibitors. Reactions used the Taqman Environmental Mastermix 2.0 (Applied Biosystems). Assays were run in triplicate on an ABI/Applied Biosystems 7900HT thermocycler using 384-well plates. Samples that amplified at a threshold cycle (C\(_T\)) ≥50 were considered negative. Samples amplifying at a C\(_T\) of <50 in 2 or more wells were considered positive. Quantification standards were created by growing *Bd* isolate JEL 197 on 1% tryptone agar and zoospores were harvested by rinsing plates with 1× phosphate buffered saline. After collection, zoospores were counted 3 times on a hemocytometer to determine a range of zoospores ml\(^{-1}\). Standard curves were generated with 10-fold serial dilutions (range: 1 × 10\(^6\) to 1 × 10\(^{-2}\) zoospores ml\(^{-1}\)). In addition to positive controls (quantification standards), each plate included a negative control (Taqman mastermix and no sample DNA) as well as 4 positive and negative quality assurance controls consisting of swabs either inoculated with *Bd* zoospores or sham-inoculated, respectively. The intensity of infection in positive samples was expressed as the number of zoospore equivalents per swab (Vredenburg et al. 2010).

**RESULTS**

**Wyoming toads**

Taqman PCR was positive from 32 of 46 (69.5%) pre-treatment skin swab samples. Of the 32 PCR-positive animals, 13 (41%) had <300 zoospore equivalents per swab (range: 7–274), 4 (12.5%) had between 2000 and 6000 zoospore equivalents per swab (range: 2107–5491), 5 (15.6%) had between 10000 and 40000 zoospore equivalents per swab (range:
10,935 to 38,794) and 10 (31%) had >50,000 zoospore equivalents per swab (range: 67,906 to 1,010,590). Post-treatment PCR tests of surviving animals on 5 occasions over a 5-mo period were consistently negative, meaning that no Bd DNA was detected (Table 1).

During the 10-d treatment period, 15 (19%) of the 80 treated toads died. Of the dead toads, 14 (93%) died within the first 6 d of treatment (Day 1, n = 1; Day 2, n = 1; Day 3, n = 3; Day 4, n = 4; Day 6, n = 5; and Day 8, n = 1). Pre-treatment skin swab samples for PCR were available from 8 of the 15 animals that died during treatment. Of these toads, 7 (87.5%) had >50,000 zoospore equivalents per swab and 1 (12.5%) had 54,911 zoospore equivalents per swab. Of the 5 toads with between 10,000 and 40,000 zoospore equivalents per swab, all (100%) survived the treatment period and of the 10 toads with >50,000 zoospore equivalents per swab, only 3 (30%) survived the treatment period.

On necropsy examination of toads that died during the treatment period, 14 (93%) of 15 had moderate to severe histologic lesions of chytridiomycosis similar to those observed in animals that died prior to treatment. The single toad without evidence of chytridiomycosis died on Day 4 of treatment and histologic examination revealed severe chronic renal disease (glomerulosclerosis and interstitial fibrosis). Other findings on the histopathology of toads that died during the treatment period included acute pneumonia (glomerulosclerosis and interstitial fibrosis). Other tissues with intralesional bacteria, and bacterial septicemia were identified.

White’s tree frogs

Taqman PCR was positive from 6 (45%) of 11 pre-treatment skin swabs obtained from White’s tree frogs and in both (100%) of the African bullfrogs. Of the PCR-positive White’s tree frogs, a single animal had 83,040 zoospore equivalents per swab and the remaining 5 positive frogs all had <100 zoospore equivalents per swab (range: 2.5 to 51). The 2 African bullfrogs had 38 and 94,859 zoospore equivalents per swab. Post-treatment PCR tests of surviving animals were consistently negative (no Bd DNA detected) on 4 occasions over a 2-mo period and on a single occasion 13 mo after cessation of treatment (Table 2).

During the 10-d treatment period, a single White’s tree frog died on the ninth treatment day. The other 10 White’s tree frogs and both African bullfrogs survived. The White’s tree frog that died had the highest infection intensity in pre-treatment testing (83,040 zoospore equivalents per swab). On necropsy examination, there was histiocytic inflammation in multiple tissues with intrasexual bacteria, and bacterial septicemia was the likely cause of death. Histologic examination of the skin demonstrated moderate epidermal hyperplasia and hyperkeratosis; however, no remaining thalli of Bd were identified.

DISCUSSION

In these outbreaks of naturally occurring chytridiomycosis, treatment with itraconazole baths was associated with elimination of Bd infection in animals that survived the treatment period. The itraconazole concentrations used for the White’s tree frog treatments and for most of the Wyoming toad treatments were significantly lower than the 100 mg l⁻¹ dose widely used in captive amphibians. Because the 100 mg l⁻¹ dose was empirically derived in the original treatment report (Nichols et al. 2000) and because very low doses appear to be effective in tadpoles (Garner et al. 2009), our observations suggest that further evaluation of reduced-dose itraconazole treatment protocols is warranted. The Wyoming toads did receive the standard 100 mg l⁻¹ dose.

Table 1. Outbreak 1. Summary of real-time Taqman PCR tests for Batrachochytrium dendrobatidis performed on a captive colony of Wyoming toads Anaxyrus baxteri during and after an outbreak of chytridiomycosis. Animals were treated with itraconazole between 15 and 24 December 2009.

<table>
<thead>
<tr>
<th>Date (mo/d/yr)</th>
<th>No. tested</th>
<th>No. positive</th>
<th>% positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/15/2009</td>
<td>46</td>
<td>32</td>
<td>69.5</td>
</tr>
<tr>
<td>1/10/2010</td>
<td>79</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2/11/2010</td>
<td>78</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3/11/2010</td>
<td>78 pooled (25 swabs)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4/14/2010</td>
<td>78 pooled (24 swabs)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5/23/2010</td>
<td>74 pooled (21 swabs)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2. Outbreak 2. Summary of real-time Taqman PCR tests for Batrachochytrium dendrobatidis performed on a captive colony of White’s tree frogs Litoria caerulea during and after an outbreak of chytridiomycosis. Animals were treated with itraconazole between 13 and 22 January 2010.

<table>
<thead>
<tr>
<th>Date (mo/d/yr)</th>
<th>No. tested</th>
<th>No. positive</th>
<th>% positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/13/2010</td>
<td>11</td>
<td>5</td>
<td>45</td>
</tr>
<tr>
<td>2/8/2010</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2/12/2010</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2/22/2010</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3/10/2010</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
itraconazole dose for the first 3 d of treatment, and it is possible that this dose alone was responsible for any beneficial effects of itraconazole. A weakness of our report is that a controlled clinical trial could not be performed (Berger et al. 2010). In a controlled trial, the ability would exist to compare elimination of \( Bd \) from itraconazole-treated infected animals as well as untreated infected animals, and therefore definitively distinguish treatment-associated clearance of infection from spontaneous treatment-independent clearance of infection. However, we consider spontaneous clearance of \( Bd \) infection unlikely because both Wyoming toads and White’s tree frogs are very susceptible to lethal \( Bd \) infection (Jennings et al. 2001, Voyles et al. 2009) and because 8 (53%) of 15 treated Wyoming toads that had very likely lethal infection intensities of >10,000 zoospore equivalents per swab (>10,000 zoospore equivalents per swab is associated with declines of \( Rana muscosa \); see Vredenburg et al. 2010) survived treatment and became \( Bd \)-negative during serial post-treatment PCR testing.

Several deaths occurred in Wyoming toads during the first 6 d of treatment; however, most of these animals had the highest \( Bd \) infection intensities — over 50,000 zoospore equivalents per swab — and severe skin lesions consistent with lethal chytridiomycosis were observed on histologic examination of the skin. Many also had concurrent medical conditions such as bacterial pneumonia or chronic kidney disease (pre-dating itraconazole treatment), which are likely to have affected survival. These observations suggest that very high infection intensities and confounding factors such as concurrent medical conditions should be considered when evaluating success or failure of treatment protocols. We cannot exclude the possibility that itraconazole treatment may have contributed to the deaths of some toads with the very highest infection intensities, and this question can only be answered in a prospective experimental trial. Finally, severe chytridiomycosis results in hyponatremia and hypokalemia (Voyles et al. 2009), and these potentially lethal disturbances in electrolyte balance were not addressed in the treatment protocol for Wyoming toads. Supportive treatments of electrolyte replacement as well as antibiotics for secondary bacterial infection have been suggested for animals severely ill with chytridiomycosis, and perhaps could have improved the treatment outcome (Berger et al. 2010, Pessier & Mendelson 2010).

This clinical report is unique because clearance of \( Bd \) infection was documented by repeated PCR tests over several months of post-treatment monitoring. Despite the ability of available PCR techniques to detect very small amounts of \( Bd \) DNA, false-negative tests do occur in individual animals with very light (low intensity) \( Bd \) infections. One proposed strategy to increase confidence that individual animals are truly negative for \( Bd \) is to obtain 3 separate PCR samples over a 14-d period (Hyatt et al. 2007). Because low-intensity \( Bd \) infections are a possible outcome following an unsuccessful antifungal treatment regime, the use of multiple post-treatment PCR tests has been advocated for evaluation of \( Bd \) treatment success in clinical trials (Berger et al. 2010). The extent of post-treatment PCR monitoring described in this report is impractical or cost-prohibitive for most amphibian programs, but the examples are useful for an initial evaluation of lower-dose itraconazole treatment regimes.

We hope that these case studies will encourage examination of low-dose or alternative itraconazole protocols in prospective experimental trials of treatment methods for \( Bd \) infection. Studies that may be of interest include determination of the lowest effective dose, the number of days required for successful treatment, the value of adjunct treatments such as electrolyte supplementation and, if treatment improves or worsens, clinical outcome for animals with very high-intensity \( Bd \) infection.

While awaiting the results of experimental trials, the use of reduced-dose itraconazole could be considered for the empirical treatment of \( Bd \)-infected amphibians. Use of a 50 mg l\(^{-1}\) dose could double the number of animals treated with a single bottle of the commercially available oral itraconazole solution and this cost savings would be especially valuable for amphibian rescue programs that often rely on donated supplies (Gagliardo et al. 2008). Furthermore, a lower itraconazole dose might reduce the risk of dose-related adverse reactions to either itraconazole itself or to the solvents used to manufacture the commercially available itraconazole solution. The decision to use a reduced-dose itraconazole treatment protocol should be carefully considered by the attending veterinarian, recognizing that almost all of the treatment methods for chytridiomycosis proposed to date have shown inconsistent results in terms of efficacy or safety (Woodhams et al. 2012). Our suggestions for the application and evaluation of itraconazole treatments are based on our experiences described in this report and from a consensus of amphibian veterinarians attending a 2009 amphibian disease workshop at the San Diego Zoo (Pessier & Mendelson 2010). Briefly, these include:
(1) Treatment with itraconazole even at a reduced dose may not be tolerated or effective in all amphibian species or life stages (e.g. tadpole, juvenile and adult). If there is no prior experience with the use of itraconazole in a particular species or life stage, treatment should first be tried on a small number of animals to evaluate safety before treating a larger group. Treatment should be halted if unexpected numbers of deaths occur during treatment, remembering that some mortality may be expected for animals severely ill with chytridiomycosis.

(2) Itraconazole baths using either the 50 mg l\(^{-1}\) reduced dose or the standard 100 mg l\(^{-1}\) dose are applied as a 5-min daily bath for 10 consecutive days. Baths should be agitated to ensure that treatment solution reaches all skin surfaces and animals should be returned to a Bd-free enclosure each day. Preparing the itraconazole baths in an electrolyte solution such as amphibian Ringer’s is suggested. However, it should be recognized that all factors such as length of daily baths, duration of treatment, the use of electrolyte solutions and a decision whether to rinse residual itraconazole from the skin of animals after treatment are empirically derived and determination of their importance or benefit awaits experimental trials.

(3) If possible, the efficacy of treatment should be evaluated by post-treatment PCR testing. This testing should begin at 2 wk or more after the last treatment application to allow for shedding of dead Bd organisms that could still result in a positive PCR test or in the case of a treatment failure, allow the remaining viable organisms to proliferate to levels detectable by PCR. The use of multiple post-treatment PCR tests may increase confidence in negative post-treatment test results. The development of optimal post-treatment testing protocols could be the subject of additional experimental trials.

Acknowledgements. The authors thank I. Navarrete, T. Tucker, K. Benson, J. Burchell and Y. Cates for outstanding PCR, database and histology support. J. Longcore kindly provided Bd isolate JEL 197 used to generate PCR standards. This project was supported by National Leadership Program grant LG-25-08-0066 from the Institute for Museum and Library Services. Any views, findings, conclusions or recommendations expressed in this publication do not necessarily represent those of the Institute of Museum and Library Services.

LITERATURE CITED


Dynamics of an emerging disease drive large scale amphibian population extinctions. Proc Natl Acad Sci USA 107:9689–9694


Editorial responsibility: Cynthia Carey,
Boulder, Colorado, USA

Submitted: December 21, 2011; Accepted: March 29, 2012
Proofs received from author(s): June 20, 2012